Search

Previous studies have demonstrated the involvement of the solute carrier family 17 member 9 (SLC17A9) in certain types of cancer; however, the precise role of SLC17A9 is not well defined. In the present study, a comprehensive analysis was performed to determine the involvement of SLC17A9 in a pan-cancer panel. First, data on SLC17A9 expression levels from publicly available databases were obtained to determine SLC17A9 expression profiles in various types of cancer. Next, the involvement of SLC17A9 in the prognosis of patients, stemness indices and the immune microenvironment was examined in 34 types of cancer. Furthermore, CCK-8 and colony-formation assays were performed to determine the effect of SLC17A9 on osteosarcoma (OSS) cells. In a pan-cancer panel, a difference in SLC17A9 expression levels was observed in the tumor tissues as compared with healthy tissues. Furthermore, survival analysis revealed a significant association between SLC17A9 expression levels and the prognosis of patients with various cancer types, including adrenocortical carcinoma, kidney renal clear cell carcinoma, glioblastoma, kidney renal papillary cell carcinoma, low grade glioma, liver hepatocellular carcinoma, mesothelioma, lung adenocarcinoma, skin cutaneous melanoma, uveal melanoma, stomach adenocarcinoma and OSS. The results of the present study revealed correlations between stemness indices, tumor immunity and SLC17A9 expression levels. Furthermore, univariate and multivariate Cox regression analyses indicated that SLC17A9 may be utilized as an independent risk factor for overall survival of patients with OSS. In vitro experiments demonstrated that SLC17A9 promotes the proliferation and viability of OSS cells. Taken together, the results of the present study suggest an association between SLC17A9 and the prognosis of patients as well as tumor immunity in various cancer types. SLC17A9 may serve as a novel prognostic biomarker and target for improving the prognosis of patients with OSS. [ABSTRACT FROM AUTHOR]